JUNE 18, 2021

Biophytis announces new convertible bonds financing up to u20ac32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for u20ac6 million
Fullscreen Mode

Other Press Releases

Paris (France), Cambridge (Massachusetts, USA), March 13, 2026 – 07:30 a.m, CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a pioneer in developing transformative therapies targeting…

Read more

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and…

Read more

Biophytis SA today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription…

Read more

Biophytis SA announces several amendments to the bond financing announced on August 5, 2025, in joint agreement with Hexagon Capital Fund.

Read more

Biophytis announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia…

Read more

Biophytis announces its participation in two leading healthcare and investment events in January 2026.

Read more